Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its position in shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPNFree Report) by 27.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 297,452 shares of the biotechnology company’s stock after acquiring an additional 63,196 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.51% of Alpine Immune Sciences worth $5,669,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Allspring Global Investments Holdings LLC raised its position in Alpine Immune Sciences by 745.5% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,488 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 1,312 shares during the last quarter. AJOVista LLC acquired a new position in shares of Alpine Immune Sciences during the 4th quarter worth approximately $64,000. Barclays PLC raised its position in shares of Alpine Immune Sciences by 44.3% during the 3rd quarter. Barclays PLC now owns 9,126 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 2,801 shares during the last quarter. New York State Common Retirement Fund lifted its stake in Alpine Immune Sciences by 75.8% in the 3rd quarter. New York State Common Retirement Fund now owns 9,634 shares of the biotechnology company’s stock valued at $110,000 after buying an additional 4,155 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Alpine Immune Sciences by 429.8% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,723 shares of the biotechnology company’s stock valued at $128,000 after buying an additional 5,454 shares during the last quarter. Institutional investors and hedge funds own 75.17% of the company’s stock.

Alpine Immune Sciences Trading Up 0.0 %

Alpine Immune Sciences stock opened at $64.97 on Tuesday. Alpine Immune Sciences, Inc. has a 52 week low of $8.33 and a 52 week high of $65.00. The stock has a market cap of $4.46 billion, a P/E ratio of -101.52 and a beta of 0.97. The stock has a 50 day moving average of $58.56 and a 200-day moving average of $36.69.

Alpine Immune Sciences (NASDAQ:ALPNGet Free Report) last posted its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.15. The firm had revenue of $7.03 million for the quarter, compared to the consensus estimate of $5.50 million. Alpine Immune Sciences had a negative net margin of 65.17% and a negative return on equity of 14.86%. As a group, equities analysts predict that Alpine Immune Sciences, Inc. will post -1.74 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ALPN has been the subject of a number of analyst reports. Royal Bank of Canada reissued a “sector perform” rating and issued a $65.00 price target (up from $41.00) on shares of Alpine Immune Sciences in a report on Thursday, April 11th. Wolfe Research reaffirmed a “peer perform” rating on shares of Alpine Immune Sciences in a research note on Thursday, April 11th. Wedbush reissued a “neutral” rating and issued a $65.00 price objective on shares of Alpine Immune Sciences in a research report on Thursday, May 16th. Leerink Partnrs lowered shares of Alpine Immune Sciences from an “outperform” rating to a “market perform” rating in a research report on Thursday, April 11th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $65.00 price target (up from $47.00) on shares of Alpine Immune Sciences in a report on Thursday, April 11th. Eight research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, Alpine Immune Sciences presently has an average rating of “Hold” and a consensus price target of $52.33.

Check Out Our Latest Report on ALPN

About Alpine Immune Sciences

(Free Report)

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.

Recommended Stories

Want to see what other hedge funds are holding ALPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alpine Immune Sciences, Inc. (NASDAQ:ALPNFree Report).

Institutional Ownership by Quarter for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.